(especial para SIIC © Derechos reservados)

Autores comunican

São Paulo, Brasil (especial para SIIC):
Os mecanismos que determinam o clearance ou a persistência da infecção viral nas hepatites virais crônicas não estão ainda bem identificados. O progresso no conhecimento sobre as ferramentas genéticas moleculares tem permitido detectar variações na resposta imune, que freqüentemente são associadas com polimorfismos do genoma humano. As diferenças na susceptibilidade do hospedeiro para as doenças infecciosas e a intensidade das doenças não podem ser atribuídas apenas à virulência do agente microbiano. Neste artigo são discutidos vários avanços recentes no conhecimento sobre a influência dos genes humanos nas hepatites crônicas B e C, a saber: a) As associações entre os polimorfismos HLA e a susceptibilidade ou resistência às doenças hepáticas virais; b) Alelos protetores influenciando as hepatites virais B (HVB) e C (HVC); c) Alelos prejudiciais influenciando HVB e HVC; d) Genes candidatos associados com a evolução clínica de HVB e HVC (genes que influenciam as células estreladas do fígado, a produção de TGF-b1 e TNF-a, os depósitos de ferro hepáticos, a produção de angiotensina II, entre outros). O conhecimento das associações genéticas com as hepatites virais crônicas pode fornecer indícios para o pleno entendimento de como se desenvolvem as suas complicações terminais, como a cirrose e o carcinoma hepatocelular. Em futuro próximo, a análise do genoma humano será capaz de elucidar o curso natural de uma hepatite viral, bem como a sua resposta à terapêutica.

Dahir Ramos de Andrade Júnior *

Referencias bibliográficas

1. ABBAS, A.K.; LICHTMAN, A.H. & POKER, J.S. - Cellular and molecular immunology, 3.ed., Philadelphia, W.B. Saunders, 1997.
2. AHN, S.H.; HAN, K.H.; PARK, J.Y. et al. - Association between hepatitis B virus infection and HLA-DR type in Korea. Hepatology, 31: 1371–1373, 2000.
3. AIKAWA, T.; KOJIMA, M.; ONISHI, H. et al. - HLA DRB1 and DQB1 alleles and haplotypes influencing the progression of hepatitis C. J. med. Virol., 49: 274-278, 1996.
4. ALMARRI, A. & BATCHELOR, J.R. - HLA and hepatitis B infection. Lancet, 344: 1194-1195, 1994.
5. ALRIC, L.; FORT, M.; IZOPET, J. et al. - Genes of the major histocompatibility complex II influence the outcome of hepatitis C virus infection. Gastroenterology, 113: 1675-1681, 1997.
6. ANONYMOUS - Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. MMWR, 47: 1-39, 1998.
7. AWAD, M.R.; EL-GAMEL, A.; HASLETON, P. et al. - Genotypic variation in the transforming growth factor-beta 1 gene: association with transforming growth factor-beta 1 production, fibrotic lung disease and graft fibrosis after lung transplantation. Transplantation, 66: 1014-1020, 1998.
8. BAKER, S.J. & REDDY, E.P. - Transducers of life and death: TNF receptor superfamily and associated proteins. Oncogene, 12: 1-9, 1996.
9. BARRETT, S.; RYAN, E. & CROWE, J. - Association of the HLA-DRB1*01 allele with spontaneous viral clearance in an Irish cohort infected with hepatitis C virus via contaminated anti-D immunoglobulin. J. Hepatol., 30: 979-983, 1999.
10. BATALLER, R.; GINES, P.; GORBIG, M.N.; NICOLAS, J.M.; GARCIA-RAMALLO, E.; ARROYO, V. & RODES J. - Angiotensin II induces contraction and is motogenic for culture human hepatic stellate cells. Antagonization by losartan and modulation by vasodilators [Abstract]. Hepatology, 28 (suppl): 437A, 1998.
11. BEDOSSA, P. & PARADIS, V. - Transforming growth factor-beta (TGF-beta): a key-role in liver fibrogenesis. J.Hepat., 22 (suppl. 2): 37-42, 1995.
12. BELLAMY, R.; RUWENDE, C.; CORRAH, T. et al. - Variations in the NRAMP 1 gene and susceptibility to tuberculosis in West Africans.
New Engl. J. Med., 338: 640-644, 1998.
13. BELLAMY, R.; RUWENDE, C.; CORRAH, T.; McADAM, K.P.; THURSZ, M.; WHITTLE, H.C. & HILL, A.V. - Tuberculosis and chronic hepatitis B virus infection in Africans and variation in the vitamin D receptor gene. J. infect. Dis., 179: 721-724, 1999.
14. BONKOVSKY, H.L.; BANNER, B.F. & ROTHMAN, A.L. - Iron and chronic viral hepatitis. Hepatology, 25: 759-768, 1997.
15. CARRINGTON, M.; MARTI, D.; WADE, J. et al. - Microsatellite markers in complex disease: mapping disease associated regions within in the human major histocompatibility complex. In: GOLDSTEIN, DB. & SCHOTTERER, C. ed. – Microsatellites: evolution and applications. Oxford, Oxford University Press, 1999, p. 225-237.
16. CARRINGTON, M.; NELSON, G.W.; MARTIN, M.P. et al. - HLA and HIV-1: heterozygote advantage and B* 35-Cw* 04 disadvantage. Science, 283: 1748-1752, 1999.
17. CONGIA, M.; CLEMENT, M.G.; DESSI, C. et al. - HLA class II genes in chronic hepatitis C virus infection and associated immunological disorders. Hepatology, 24: 1338-1341, 1996.
18. CRAMP, M.E.; CARUCCI, P.; UNDERHILL, J. et al. - Association between HLA class II genotype and spontaneous clearance of hepatitis B viraemia. J. Hepat., 29: 207-213, 1998.
19. DENG, H.; LIU, R.; ELLMEIER, W. et al. - Identification of a major co-receptor for primary isolates of HIV-1. Nature, 381: 661-666, 1996.
20. DIB, C.; FAURE, S.; FIZAMES, C. et al. - A comprehensive genetic map of the human genome based on 5,264 microsatellites. Nature, 380: 152-154, 1996.
21. DOHERTY, P.C. & ZINKERNAGEL, R.M. - Enhanced immunological surveillance in mice heterozygous at the H-2 gene complex. Nature, 256: 50-52, 1975.
22. DONALDSON, P.T.; DOHERTY, D.G.; HAYLLAR, K.M. et al. – Susceptibility to autoimmune chronic active hepatitis: human leukocyte antigens DR4 and A1-B8-DR3 are independent risk factors. Hepatology, 13: 701-706, 1991.
23. TROWSDALE, J. - Molecular genetics of HLA class I and class II regions. In: BROWNING, M. & McMICHAEL, A. ed. HLA and MHC: genes molecules and function. Oxford, Bios Scientific, 1996, p. 23-37.
24. FANNING, L.; KENNY, E.; SHEEHAN, M. et al. - Viral load and clinicopathological features of chronic hepatitis C (1b) in a homogeneous patient population. Hepatology, 29: 904-906, 1999.
25. FANNING, L.J.; LEVIS, J.; KENNY-WALSH, E. et al. - Viral clearance in hepatitis C (1b) infection: relationship with human leukocyte antigen class II in a homogeneous population. Hepatology, 31: 1334-1337, 2000.
26. FEDER, J.N.; GNIRKE, A.; THOMAS, W. et al. - A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis. Nature Genetics, 13: 399-408, 1996.
27. FUJISAWA, T.; IKEGAMI, H.; KAWAGUCHI, Y. et al. – Class I HLA is associated with age-at-once of IDDM, while class II HLA confers susceptibility to IDDM. Diabetologia, 38: 1493 – 1495, 1995.
28. GIBBONS, G.H.; PRATT, R.E. & DZAU, V.J. - Vascular smooth muscle cell hypertrophy vs hyperplasia: autocrine transforming growth factor b1 expression determines growth responses to angiotensin II. J. clin. Invest., 90: 456-461, 1992.
29. GIORDANO, M.; OEFNER, P.J.; UNDERHILL, P.A. et al. – Identification by denaturing high-performance liquid chromatography of numerous polymorphisms in a candidate region for multiple sclerosis susceptibility. Genomics, 56: 247-253, 1999.
30. GUIDOTTI, L.G.; ISHIKAWA, T.; HOBBS, M.V. et al. - Intracellular inactivation of the hepatitis B virus by cytotoxic T lymphocytes. Immunity, 4: 25-36, 1996.
31. HEZODE, C.; CAZENEUVE, C.; COUE, O. et al. - Hemochromatosis Cys 282 Tyr mutation and liver iron overload in patients with chronic active hepatitis C. Hepatology, 27: 306, 1998.
32. HIGASHI, Y.; KAMIKAWAJI, N.; SUKO, H. & ANDO, M. - Analysis of HLA alleles in Japanese patients with cirrhosis due to chronic hepatitis C. J. Gastroent. Hepat., 11: 241-246, 1996.
33. HOHLER, T.; GERKEN, G.; NOTGHI, A. et al. - MHC class II genes influence the susceptibility to chronic active hepatitis C. J. Hepat., 27: 259-264, 1997.
34. HOHLER, T.; GERKEN, G.; NOTGHI, A. et al. - HLA-DRB1*1301 and *1302 protect against chronic hepatitis B. J. Hepat., 26: 503-507, 1997.
35. HOHLER, T.; KRUGER, A.; GERKEN, G. et al. - Tumor necrosis factor alpha promoter polymorphism at position –238 is associated with chronic active hepatitis C infection. J. med. Virol., 54: 173-177, 1998.
36. HOHLER, T.; KRUGER, A.; GERKEN, G. et al. - A tumor necrosis factor-alpha (TNF-alpha) promoter polymorphism is associated with chronic hepatitis B infection. Clin. exp. Immunol., 111: 579-582, 1998.
37. HUE, S.; CACOUB, P.; RENOU, C. et al. - Human leukocyte antigen class II alleles may contribute to the severity of hepatitis C virus-related liver disease. J. infect. Dis., 186: 106-109, 2002.
38. JIANG, Y.G.; WANG, Y.M.; LIU, T.H. & LIU, J. - Association between HLA class II gene and susceptibility or resistance to chronic hepatitis B. Wld J. Gastroent., 9: 2221 – 2225, 2003
39. KAZEMI-SHIRAZI, L.; DATZ, C.; MAIER-DOBERSBERGER, T. et al. - The relation of iron status and hemochromatosis gene mutations in patients with chronic hepatitis C. Gastroenterology, 116: 127-134, 1999.
40. KENNY-WALSH, E. - Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. Irish Hepatology Research Group. New Engl. J. Med., 340: 1228-1233, 1999.
41. KNODELL, R.G.; ISHAK, K.G.; BLACK, W.C. et al. - Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology, 1: 431-435, 1981.
42. KOZIEL, M.J.; DUDLEY, D.; AFDHAL, N. et al. - HLA class I – restricted cytotoxic T lymphocytes specific for hepatitis C virus – Identification of multiple epitopes and characterization of patterns of cytokine release. J. clin. Invest., 96: 2311-2321, 1995.
43. KUZUSHITA, N.; HAYASHI, N.; KATAYAMA, K. et al. - Increased frequency of HLA DR13 in hepatitis C virus carriers with persistently normal ALT levels. J. med. Virol., 48: 1-7, 1996.
44. KUZUSHITA, N.; HAYASHI, N.; MORIBE, T. et al. - Influence of HLA haplotypes on the clinical courses of individuals infected with hepatitis C virus. Hepatology, 27: 240-244, 1998.
45. LEE, W.M. - Hepatitis B virus infection. New Engl. J. Med., 337: 1733-1745, 1997.
46. LECHMANN, M.; SCHNEIDER, E.M.; GIERS, G. et al. - Increased frequency of the HLA-DR15 (B1*15011) allele in German patient with self-limited hepatitis C virus infection. Europ. J. clin. Invest., 29: 337-343, 1999.
47. LIN, T.M.; CHEN, C.J.; WU, M.M. et al. - Hepatitis B virus markers in Chinese twins. Anticancer Res., 9: 737-741, 1989.
48. LONG, K.Z. & SANTOS, J.I. - Vitamins and the regulation of the immune response. Pediat. infect. Dis., 18: 283-290, 1999.
49. MANGIA, A.; GENTILE, R.; CASCAVILLA, I. et al. - HLA class II favors clearance of HCV infection and progression of the chronic liver damage. J. Hepat., 30: 984-989, 1999.
50. MARTINSON, J.J.; CHAPMAN, N.H.; REES, D.C.; LIU, Y.T. & CLEGG, J.B. - Global distribution of the CCR5 gene 32-basepair deletion. Nature Genet., 16: 100-103, 1997.
51. McKIERNAN, S.M.; HAGAN, R.; CURRY, M.; HEGARTY, J.; LAWLOR, E. & KELLEHR, D. - Human leucocyte antigens related to disease outcome in hepatitis C [Abstract]. Hepatology, 28 (suppl): 214A, 1998.
52. McKIERNAN, S.M.; HAGAN, R.; CURRY, M. et al. - The MHC is a major determinant of viral status but not fibrotic stage, in individuals infected with hepatitis C. Gastroenterology, 118: 1124-1130, 2000.
53. MINTON, E.J.; SMILLIE, D.; NEAL, K.R. et al. - Association between MHC class II alleles and clearance of circulating hepatitis C virus. J. infect. Dis., 178: 39-44, 1998.
54. MOTA, A.H.; FAINBOIM, H.; TERG, R. & FAINBOIM, L. - Association of chronic active hepatitis and HLA B35 in patients with hepatitis B virus. Tissue Antigens, 30: 238-240, 1987.
55. PEANO, G.; MENARDI, G.; PONZETTO, A. & FENOGLIO, L.M. - HLA-DR5 antigen: a genetic factor influencing the outcome of hepatitis C virus infection ? Arch. intern .Med., 154: 2733-2736, 1994.
56. POWELL, E.E.; EDWARDS-SMITH, C.J.; HAY, J.L. et al. - Host genetic factors influence disease progression in chronic hepatitis C. Hepatology, 31: 828-833, 2000.
57. POWER, J.P.; LAWLOR, E.; DAVIDSON, F. et al. - Hepatitis C viraemia in recipients of Irish intravenous anti-D immunoglobulin. Lancet, 344: 1166-1167, 1994.
58. POWER, J.P.; LAWLOR, E.; DAVIDSON, F. et al. - Molecular epidemiology of an outbreak of infection with hepatitis C virus in recipients of anti-D immunoglobulin. Lancet, 345: 1211-1213, 1995.
59. POYNARD, T.; BEDOSSA, P. & OPOLON, P. - Nature history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet, 349: 825-832, 1997.
60. RACIOPPI, L.; RONCHESE, F.; SCHWARTZ, R.H. & GERMAIN, R.N. – The molecular basis of class II MHC allelic control of T cell responses. J. Immunol., 147: 3718 – 3727, 1991.
61. RENOU, C.; HALFON, P.; POL, S. et al. - Histological features and HLA class II alleles in hepatitis C virus chronically infected patients with persistently normal alanine aminotransferase levels. Gut, 51: 585-590, 2002.
62. SHERON, N.; LAU, J.; DANIELS, H. et al. - Increased production of tumour necrosis factor alpha in chronic hepatitis B virus infection. J. Hepat., 12: 241-245, 1991.
63. SMITH, B.C.; GORVE, J.; GUZAIL, M.A. et al. - Heterozygosity for hereditary hemochromatosis is associated with more fibrosis in chronic hepatitis C. Hepatology, 27: 1695-1699, 1998.
64. STEEL, C.M.; LUDLAM, C.A.; BEATSON, D. et al. – HLA haplotype A1 B8 DR3 at a risk factor for HIV-related disease. Lancet, 1: 1185-1188, 1988.
65. SUMMERFIELD, J.A.; RYDER, S.; SUMIYA, M. et al. - Mannose binding protein gene mutations associated with unusual and severe infection in adults. Lancet, 345: 886-889, 1995.
66. TEWS, B.; WILHELM, J.; SUMMERER, D. et al. – Application of the C4’alkylated deoxyribose primer system (CAPS) in allele-specific real-time PCR for increased selectivity in discrimination of single nucleotide sequence variants. Biol. Chem., 384: 1533-1541, 2003.
67. THIO, C.L; CARRINGTON, M.; MARTI, D. et al. - Class II HLA alleles and hepatitis B virus persistence in African Americans. J. infect. Dis., 179: 1004-1006, 1999.
68. THIO, C.L.; THOMAS, D.L, & CARRINGTON, M. - Chronic viral hepatitis and the human genome. Hepatology, 31: 819-827, 2000.
69. THIO, C.L.; THOMAS, D.L.; GOEDERT, J.J. et al. - Racial differences in HLA class II associations with hepatitis C virus outcomes. J. infect. Dis., 184: 16-21, 2001.
70. THIO, C.L.; GAO, X.; GOEDERT, J.J. et al. - HLA-Cw*04 and hepatitis C virus persistence. J. Virol., 76: 4792-4797, 2002.
71. THIO, C.L.; THOMAS, D.L.; KARACKI, P. et al. - Comprehensive analysis of class I and class II HLA antigens and chronic hepatitis B virus infection. J. Virol., 77: 12083- 12087, 2003.
72. THOMAS, H.C.; FOSTER, G.R.; SUMIYA, M. et al. - Mutation of gene of mannose-binding protein associated with chronic hepatitis B viral infection. Lancet, 348: 1417-1419, 1996.
73. THURSZ, M.R.; KWIATKOWSKI, D.; ALLSOPP, C.E.M. et al. - Association between an MHC class II allele and clearance of hepatitis B virus in the Gambia. New Engl. J. Med., 332: 1065-1069, 1995.
74. TIBBS, C.; DONALDSON, P.; UNDERHILL, J.A. et al. - Evidence that the HLA DQA1*03 allele confers protection from chronic HCV-infection in Northern European Caucasoids. Hepatology, 24: 1342-1345, 1996.
75. TILLMANN, H.L.; CHEN, D.F.; TRAUTWEIN, C. et al. - Low frequency of HLA-DRB1*11 in hepatitis C virus induced end stage liver disease. Gut, 48: 714-718, 2001.
76. TURNER, D.M.; WILLIAMS, D.M.; SANKARAN, D. et al. - An investigation of polymorphism in the interleukin-10 gene promoter. Europ. J. Immunogenet., 24: 1-8, 1997.
77. VAN HATTUM, J.; SCHREUDER, G.M. & SCHALM, S.W. – HLA antigens in patients with various courses after hepatitis B virus infection. Hepatology, 7: 11-14, 1987.
78. VERDON, R.; POL, S.; LANDAIS, P. et al. - Absence of association between HLA antigens and chronicity of viral hepatitis in haemodialized patients. J. Hepat., 21: 388-393, 1994.
79. VILLANO, S.A.; VLAHOV, D.; NELSON, K.E. et al. - Persistence of viremia and the importance of long-term follow-up after acute hepatitis C infection. Hepatology, 29: 908-914, 1999.
80. WANG, S.C.; OHATA, M.; SCHRUM, L.; RIPPE, R.A. & TSUKAMOTO, H. - Expression of interleukin-10 by in vitro and in vivo activated hepatic stellate cells. J. biol. Chem., 273: 302-308, 1998.
81. WILSON, A.G.; DE VRIES, N.; PACIOT, F. et al. - An allelic polymorphism within the human tumor necrosis factor alpha promoter region is strongly associated with HLA-A1, B8 and DR3 alleles. J. exp. Med., 177: 557-560, 1993.
82. WILSON, A.G.; DI GIOVINE, F.S.; BLAKEMORE, A.I. & DUFF, G.W. - Single base polymorphism in the human tumour necrosis factor alpha (TNF-alpha) gene detectable by Ncol restriction of PCR product. Hum. Molec. Genet., 1: 353, 1992.
83. YENIGUN, A. & DURUPINAR, B. - Decreased frequency of the HLA-DRB1*11 allele in patients with chronic hepatitis C virus infection. J. Virol., 76: 1787-1789, 2002.
84. YOSHIZAWA, K.; OTA, M.; SAITO, S. et al. - Long-term follow-up of hepatitis C virus infection: HLA class II loci influences the natural history of the disease. Tissue Antigens, 61: 159-165, 2003.
85. ZAVAGLIA, C.; BORTOLON, C.; FERRIOLI, G et al. – HLA typing in chronic type B, D and C hepatitis. J. Hepat., 24: 658-665, 1996.

Para comunicarce con Dahir Ramos de Andrade Júnior mencionar a SIIC como referencia:
Av. Paes de Barros 1540, Ap. 41, Mooca, São Paulo, 03114-001, São Paulo, São Paulo, Brasil
Fono: 11 69668948; Fax: 11 30667029
dahira@uol.com.br

THE INFLUENCE OF THE HUMAN GENOME ON CHRONIC VIRAL HEPATITIS OUTCOME

Título en castellano
A INFLUÊNCIA DO GENOMA HUMANO NO CURSO DAS HEPATITES VIRAIS CRÔNICAS

Autores
Dahir Ramos de Andrade Júnior,¹ Dahir Ramos de Andrade²

Clasificado en siicsalud